52 results on '"Ratjen F"'
Search Results
2. Feasibility of ultrashort echo time (ute) mri to evaluate the effect of lumacaftor/ivacaftor therapy in children with cystic fibrosis (cf) homozygous for f508del: P254
3. Effect of lumacaftor/ivacaftor on total, bronchiectasis, and air trapping computed tomography (ct) scores in children homozygous for f508del-cftr: exploratory imaging substudy: S93
4. The Canadian Healthy Infant Longitudinal Development (CHILD) Study: examining developmental origins of allergy and asthma
5. CANADIAN NATIONAL AIRWAY CLEARANCE STUDY: PATIENT SATISFACTION WITH POSITIVE EXPIRATORY PRESSURE VERSUS HIGH FREQUENCY CHEST WALL OSCILLATION: 397★
6. CANADIAN NATIONAL AIRWAY CLEARANCE STUDY: HOW PHYSICALLY ACTIVE ARE CF PATIENTS?: 398★
7. MULTIPLE BREATH WASHOUT PARAMETERS FOR INTERVENTIONAL STUDIES IN CF: MOMENT RATIOS COMPARED TO LCI: 371
8. FACTORS INFLUENCING TIME TO FIRST ACQUISITION OF STENOTROPHOMONAS MALTOPHILIA INFECTION IN CYSTIC FIBROSIS PATIENTS: 325
9. IS CHRONIC STENOTROPHOMONAS MALTOPHILIA INFECTION ASSOCIATED WITH MORTALITY OR LUNG TRANSPLANTATION IN CYSTIC FIBROSIS PATIENTS?: 281
10. LUNG CLEARANCE INDEX TO EVALUATE THE EFFECT OF IVACAFTOR ON LUNG FUNCTION IN SUBJECTS WITH CF WHO HAVE THE G551D-CFTR MUTATION AND MILD LUNG DISEASE: 249
11. VALIDATION OF A NITROGEN (N2) BASED MULTIPLE BREATH WASHOUT TECHNOLOGY IN HEALTHY CHILDREN AND CHILDREN WITH CYSTIC FIBROSIS: 240
12. INFANT PFTS AS AN ENDPOINT IN THE INFANT STUDY OF INHALED SALINE RANDOMIZED CONTROLLED TRIAL: 225
13. EFFECT OF HYPERTONIC SALINE ON LUNG CLEARANCE INDEX IN INFANTS AND PRESCHOOL CHILDREN WITH CF: A PILOT STUDY: 223
14. IMPACT OF ACUTE ANTIBIOTIC USAGE ON THE PULMONARY EXACERBATION ENDPOINT IN A CYSTIC FIBROSIS RANDOMIZED TRIAL: 199
15. NITROGEN MULTIPLE BREATH WASHOUT IS MORE SENSITIVE THAN SF6 BASED LCI MEASUREMENTS AT DETECTING LUNG ABNORMALITIES IN CHILDREN WITH CF: 197★
16. COLLABORATIVE TEACHING: AN INTERACTIVE, MULTI-DISCIPLINARY CYSTIC FIBROSIS TEACHING DAY: 590
17. ASSESSING THE ROLE OF SWEAT TESTING AND CFTR GENOYTPING IN NBS-POSITIVE INFANTS WITH AN UNCERTAIN CF DIAGNOSIS: 416★
18. THE CONTRIBUTION OF PULMONARY EXACERBATIONS TO LUNG FUNCTION DECLINE IN CYSTIC FIBROSIS PATIENTS: 336★
19. DOES CHRONIC STENOTROPHOMONAS MALTOPHILIA INFECTION AFFECT CLINICAL OUTCOME FOLLOWING PULMONARY EXACERBATIONS IN CYSTIC FIBROSIS PATIENTS?: 252★
20. A RANDOMIZED PLACEBO CONTROLLED STUDY ON THE EFFECTS OF L-ARGININE INHALATION IN PATIENTS WITH CYSTIC FIBROSIS: 229
21. LONG-TERM SAFETY AND EFFICACY OF INVESTIGATIONAL CFTR POTENTIATOR, VX-770, IN SUBJECTS WITH CF: 204
22. LUNG CLEARANCE INDEX AS AN OUTCOME MEASURE IN CYSTIC FIBROSIS CLINICAL TRIALS: 201★
23. BONE MINERAL DENSITY AND HABITUAL PHYSICAL ACTIVITY IN CYSTIC FIBROSIS: 647⋆
24. INHALED 7% HYPERTONIC SALINE IS WELL TOLERATED IN INFANTS AND TODDLERS WITH CF: 444⋆
25. MRSA IN A PEDIATRIC CF CLINIC POPULATION: CLINICAL AND MOLECULAR EPIDEMIOLOGY, RISK FACTORS FOR COLONIZATION, AND IMPACT ON DISEASE PROGRESSION: 434
26. CLINICAL EVALUATION OF ONCE-DAILY DOSING TOBRAMYCIN GUIDELINES IN PAEDIATRIC PATIENTS WITH CYSTIC FIBROSIS: 426
27. THE EFFECT OF CHRONIC INFECTION WITH ASPERGILLUS FUMIGATUS ON PULMONARY EXACERBATIONS AND FORCED EXPIRATORY VOLUME IN ONE SECOND IN PEDIATRIC CYSTIC FIBROSIS PATIENTS: 403
28. DEVELOPMENT OF A SEROLOGIC ASSAY TO DETECT ANTIBODIES TO S. MALTOPHILIA IN CYSTIC FIBROSIS PATIENTS: 389
29. SHORT AND LONG-TERM EFFICACY OF INHALED TOBRAMYCIN IN EARLY P. AERUGINOSA INFECTION: THE ELITE STUDY: 334⋆
30. TGFB1 GENE IS AN IMPORTANT GENETIC MODIFIER IN CHILDREN WITH CYSTIC FIBROSIS: 213
31. FACTORS INFLUENCING SPUTUM ARGINASE ACTIVITY IN CHILDREN WITH CYSTIC FIBROSIS IN STABLE DISEASE AND DURING TREATMENT OF PULMONARY EXACERBATION: 154⋆
32. Massive Hemoptysis in an 11-Year-Old Girl With Isolated Pulmonary Arteritis
33. A MULTICENTER, RANDOMIZED, DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL EVALUATING THE METABOLIC AND RESPIRATORY EFFECTS OF GROWTH HORMONE IN CHILDREN WITH CYSTIC FIBROSIS: 515★
34. ABNORMALITIES IN MUSCLE METABOLISM IN CF PATIENTS: 409*
35. DETERMINATION OF A ONCE-DAILY DOSING REGIMEN FOR TOBRAMYCIN IN PAEDIATRIC CYSTIC FIBROSIS PATIENTS: 341
36. INHALED TOBRAMYCIN NEBULISER SOLUTION FOR TREATMENT OF EARLY PSEUDOMONAS AERUGINOSA INFECTION: FIRST RESULTS FROM THE ELITE STUDY: 314⋆
37. SAFETY AND EFFICACY OF AEROSOLIZED MOLI1901 IN PATIENTS WITH CYSTIC FIBROSIS: 241*
38. A PILOT STUDY OF SAFETY AND TOLERABILITY OF INHALED HYPERTONIC SALINE IN INFANTS WITH CYSTIC FIBROSIS: 244*
39. THE ANGIOTENSIN I CONVERTING ENZYME (ACE) GENE MODIFIES LUNG DISEASE IN CHILDREN WITH CYSTIC FIBROSIS: 182*
40. Comparison of Throat Swabs and Nasopharyngeal Suction Specimens in Non-Sputum-Producing Patients With Cystic Fibrosis
41. Comment on: Pharmacokinetics of inhaled colistin in patients with cystic fibrosis
42. Nasal nitric oxide to diagnose primary ciliary dyskinesia in newborns
43. Pharmacokinetics of inhaled colistin in patients with cystic fibrosis
44. Inhaled glutathione decreases PGE2 and increases lymphocytes in cystic fibrosis lungs
45. High-dose corticosteroid therapy for bronchiolitis obliterans after bone marrow transplantation in children
46. DNA Concentrations in BAL Fluid of Cystic Fibrosis Patients With Early Lung Disease:: Influence of Treatment With Dornase Alpha
47. Matrix metalloproteases in BAL fluid of patients with cystic fibrosis and their modulation by treatment with dornase alpha
48. Different subgroups of difficult asthma in children
49. Intrapulmonary protein leakage in immunocompromised children and adults with pneumonia
50. Nitric oxide metabolites in cystic fibrosis lung disease
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.